scholarly journals Beneficial Effects of Adding Topical Atorvastatin 5% Cream to Topical Betamethasone 1% Ointment on Chronic Hand Eczema

2020 ◽  
Vol 23 (9) ◽  
pp. 605-613
Author(s):  
Maryam Mehrpooya ◽  
Fatemeh Ghaed-Amini ◽  
Farzin Firozian ◽  
Younes Mohammadi ◽  
Pedram Alirezaei
Keyword(s):  
Life Quality ◽  
Severity Index ◽  
Hand Eczema ◽  
Double Blind ◽  
Atorvastatin Group ◽  
Beneficial Effects ◽  
Chronic Hand Eczema ◽  
Dermatological Condition ◽  
Vas Scores ◽  
The Mean

Background: Hand eczema (HE) refers to a common inflammatory dermatological condition. Several studies have shown that statins may have anti-inflammatory effects. This study aimed at investigating the efficacy of adding topical atorvastatin to topical betamethasone in the treatment of chronic HE. Methods: This randomized, double-blind, placebo-controlled research was done between October 2017 and August 2018 in Hamadan, Iran. Of 130 cases treated for HE, 88 were randomly assigned to groups receiving either betamethasone 1% ointment plus atorvastatin 5% cream (n = 44) or betamethasone 1% ointment plus vehicle cream (n=44). Both groups applied their medications twice a day for 10 days. The primary outcome was changes in the severity of HE, assessed by hand eczema severity index (HECSI). The secondary outcomes were changes in itching evaluated via visual analogue scale (VAS) and quality of life examined through dermatology life quality index (DLQI). Results: Seventy-two out of 88 eligible cases completed the study. The mean HECSI scores decreased in both groups after the intervention, although the change in HECSI was greater in the atorvastatin group (adjusted mean difference [AMD]: 5.756; 95% CI: 5.168 to 6.344, P<0.001). The mean VAS scores decreased in both groups after the intervention, although the change in VAS was greater in the atorvastatin group (AMD: 10.535; 95% CI: 7.005 to 14.064, P<0.001). Treatment with topical atorvastatin was more effective in improving DLQI (AMD: 1.990; 95% CI: 1.821 to 2.158, P<0.001). Conclusion: Addition of topical atorvastatin to topical betamethasone is beneficial in treatment of chronic HE. Trial Registration: Identifier: IRCT2017070922965N10; https://www.irct.ir/.

scholarly journals Efficacy of Pumpkin Ointment in Treatment of Chronic Hand Eczema: A Randomized, Active-Controlled, Double Blind Clinical Trial

2020 ◽  
Author(s):  
Alemeh KHADEMI ◽  
Parvin MANSURI ◽  
Daryoush PAHLEVAN ◽  
Mahbubeh BOZORG ◽  
Malihe NASIRI ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Negative Impact ◽  
Life Quality ◽  
Severity Index ◽  
Hand Eczema ◽  
Herbal Remedies ◽  
Double Blind ◽  
Chronic Hand Eczema ◽  
Chronic Skin

Background: Hand Eczema (HE) is chronic skin disease with a high prevalence in population. It has negative impact on the quality of life. Due to the public interest in herbal remedies, we attempt to assess the efficacy of pumpkin ointment in treatment of chronic HE in this research. Methods: This study was conducted in an outpatient clinic at Imam-Khomeini Hospital in Tehran (Iran) from May 2015 to Nov 2016. We performed a double-blind trial on 60 patients with chronic HE randomized to four groups included pumpkin, betamethasone, eucerin and almond ointment (n=15 for each group) for 28 days. Patients were ordered to apply ointments twice a day. Hand Eczema Severity Index (HECSI) and Dermatology Life Quality Index (DLQI) of the patients were evaluated by a dermatologist on the 1st, 14th and 28th d after the start of treatment. Results: Patients’ DLQI scores in pumpkin and betamethasone group was significant and pumpkin group showed a better response in quality of life (P=0.001). Betamethasone and pumpkin ointment were effective and showed significant improvement compared with almond and eucerin and reduce HECSI scores (P=0.002 and P=0.012 respectively). Betamethasone ointment outcome on HECSI scores in comparison with topical pumpkin was significant (P<0.001). No clinically adverse effects were observed. Conclusion: Although pumpkin ointment showed a better response in patients’ DLQI in HE but it was less effective than betamethasone in decreasing HECSI.

scholarly journals PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol

2018 ◽  
Vol 45 (7) ◽  
pp. 922-928 ◽  
Author(s):  
Jessica A. Walsh ◽  
Terri Arledge ◽  
Tommi Nurminen ◽  
Luke Peterson ◽  
Jeffrey Stark
Keyword(s):  
Psoriatic Arthritis ◽  
Dermatology Life Quality Index ◽  
Certolizumab Pegol ◽  
Life Quality ◽  
Severity Index ◽  
Strong Correlations ◽  
Double Blind ◽  
Percentage Improvement ◽  
High Concordance ◽  
Psoriasis Severity

Objective.The product of physician’s global assessment and body surface area (PGA×BSA) to assess psoriasis severity has previously been investigated in patients with psoriasis, with the aim of assessing PGA×BSA as an alternative to the time-consuming Psoriasis Area and Severity Index (PASI). Here, we investigate PGA×BSA as an alternative to PASI in patients with psoriatic arthritis (PsA).Methods.Analyses used data from the double-blind, placebo-controlled, RAPID-PsA trial (NCT01087788) that investigated the efficacy of certolizumab pegol (CZP) in patients with PsA. Outcomes assessed whether the PGA×BSA and PASI results were comparable, and whether these outcomes correlated with one another or with the Dermatology Life Quality Index (DLQI).Results.For CZP-treated patients, both PGA×BSA and PASI demonstrated similar sensitivities to treatment between baseline and Week 24, with mean improvements of 77.4% and 69.0%, respectively. Similar improvements were also seen with placebo (PGA×BSA: 3.2%, PASI: 6.1%). Achievement of 75% response criterion in PGA×BSA and PASI was attained by similar proportions of patients with CZP (PGA×BSA75: 59.0%, PASI75: 61.4%) and placebo (PGA × BSA75: 15.1%, PASI75: 15.1%). Cross tabulations showed high concordance between achievement of response outcomes in PGA×BSA and PASI (79.6–95.2%). Spearman correlations revealed strong correlations between PGA×BSA and PASI at baseline (r = 0.78; n = 225) and percentage improvement to Week 24 (r = 0.85; n = 186). Both outcomes were only moderately correlated with DLQI (r = 0.41–0.50; n = 179–249).Conclusion.PGA×BSA is sensitive to changes in skin manifestations in patients with PsA treated with CZP. Further, PGA×BSA correlates strongly with PASI, and achievement of 75% improvement was similar for PGA×BSA and PASI.

scholarly journals Efficacy and Safety of Jueyin Granules for Patients with Mild-to-Moderate Psoriasis Vulgaris: Protocol for a Multicenter Randomized Placebo-Controlled Trial

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Su Li ◽  
Cang Zhang ◽  
Hong-Ya Zhang ◽  
Meng Zhou ◽  
Si-Nong Wang ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Life Quality ◽  
Severity Index ◽  
Placebo Treatment ◽  
International Standards ◽  
Physician Global Assessment ◽  
Double Blind ◽  
Objective Evidence ◽  
Multicenter Randomized Controlled Trial ◽  
Heat Syndrome

Introduction. The etiology and pathogenesis of psoriasis are complex. Blood-heat syndrome is the core pathogenesis of psoriasis. Based on theories of Chinese medicine (CM), heat-clearing and blood-cooling (HCBC) are the primary treatment. Very few studies have investigated the pharmacological mechanism of the CM HCBC method for treating psoriasis. This multicenter randomized controlled trial will focus on treating psoriasis blood-heat syndrome with the HCBC method using Jueyin granules (JYKL). This will be an objective and standardized evaluation of the efficacy, safety, and reproducibility of the HCBC method to obtain objective evidence meeting international standards that aim to establish a clinical standard suitable for the popular application of CM for treating psoriasis. Methods and Analysis. A five-center randomized double-blind placebo-controlled clinical design will be used in this study. At least 196 participants will be randomly assigned to receive either JYKL or placebo treatment approximately 30 minutes after meals in the morning and evening (one sachet per time, twice daily for 8 consecutive weeks). The study duration will be 17 weeks, including 1 week of screening, 8 weeks of intervention, and 8 weeks of follow-up. The patients will be evaluated every 2 weeks, and the measures will be compared with baseline values. The primary outcome measure will be the psoriasis lesion area severity index. We will also observe the recurrence rate, body surface area, physician global assessment, dermatology life quality index, quality of life index, visual analogue scale score, CM symptom score, combined drug use, and adverse events. This trial is registered with NCT03961230.

The Efficacy of N-acetilcysteine for the Treatment of the Metamfetamin-addicted Patients Under Methadon Therapy: A Double-blind Clinical Trial

2020 ◽  
Vol 22 (7) ◽  
Author(s):  
Farzaneh Karami ◽  
Fateme Assarian ◽  
Fatemeh Sadat Ghoreishi ◽  
Mojtaba Sehat
Keyword(s):  
Methadone Treatment ◽  
Severity Index ◽  
Addiction Severity Index ◽  
Double Blind ◽  
Addiction Severity ◽  
Methamphetamine Dependence ◽  
Double Blind Clinical Trial ◽  
The Mean ◽  
To Receive ◽  
The Brain

Background: Methamphetamine dependence is a growing global problem. Currently, there are no approved pharmacotherapy options for the management of methamphetamine dependence. One of the alternatives to manage this addiction is the use of N acetylcysteine (NAC) due to its capacity to restore homeostasis in the brain glutamate systems disrupted in addiction and its ability to reduce craving and the risk of relapse. Methods: Methamphetamine‐dependent volunteers under methadone treatment (n = 38) were randomized to receive daily doses of 1200 mg of NAC, or placebo. The participants were followed for 12 weeks (two visits weekly). Craving and Beck Inventory Depression (BDI) was determined at the beginning of the study and also after one month, two months, and three months. Addiction severity index (ASI) was recorded at the beginning of the study and after three months. The data were analyzed via SPSS version 16.0 (SPSS Inc. Chicago, Illinios, USA) Results: The mean score of craving and BDI reduced after two months with NAC treatment. ASI (e.g., substance, familial, and psychiatric categories) was significantly reduced at the end of the study in the NAC group compared to placebo (P < 0.001). The success of the treatment in groups of NAC and placebo were 84% and 73%, respectively (P = 0.001). 63.2% of the NAC group patients avoided substance use for more than a month, but this was 10.5% in the placebo group (P = 0.001). Conclusions: The NAC showed good efficacy in suppressing methamphetamine craving, addiction severity index, and depression. It may be a useful pharmacological treatment for methamphetamine dependency.

scholarly journals An Observational Study to Evaluate Quality of Life in Patients with Melasma in A Tertiary Level Hospital of Pokhara

2021 ◽  
Vol 19 (1) ◽  
pp. 37-41
Author(s):  
Prajwal Pudasaini ◽  
Saraswoti Neupane
Keyword(s):  
Quality Of Life ◽  
Age Of Onset ◽  
Life Quality ◽  
Sun Exposure ◽  
Severity Index ◽  
Cross Sectional ◽  
Medical College ◽  
The Mean ◽  
Hormonal Therapies

Introduction: Melasma is an acquired hyper melanosis that becomes more pronounced after sun exposure. Centro facial which is the commonest pattern followed by Malar and Mandibular are three clinical patterns of Melasma. Genetic influences, exposure to UV radiation, pregnancy, hormonal therapies, contribute to the pathogenesis of melasma. Melasma may considerably have significant effect on quality of life of patients.   Objectives: The present study was conducted to evaluate the effects of melasma in quality of life (QoL) in the form of DLQI (Dermatology Life Quality Index) and severity of melasma according to Melasma Area and Severity Index (MASI).   Materials and Methods: This is a hospital based cross-sectional prospective study conducted in 193 Melasma patients in the Department of Dermatology, Venereology and Leprology, Gandaki Medical College and Teaching Hospital, Pokhara from November 2018 to November 2019. MASI score was calculated and the patients were provided with a Nepali version of DLQI to fill up.   Results: This study included 193 patients. Mean age of patients with melasma was 29.4 ± 8.5 years with maximum reported age of 59 years. The Mean age of onset of disease was 26.5 years. The Mean age of onset of disease had little impact on DLQI. The mean DLQI score was 10.9 ± 5.9, thus indicating “very large effect on patient’s life”. The mean MASI score was 6.6 ± 5.2. It was found that there was no correlation between severity of disease and DLQI scores (p=0.317) Conclusion: Melasma commonly affected females during second and third decades of life. It had a very large effect on patient’s life as assessed by DLQI.    

scholarly journals Efficacy of SEBCLAIRA® Cream for Moderate Seborrhoeic Dermatitis on The Face as An Adjuvant Therapy (Randomised Clinical Trial, Double Blind)

2018 ◽  
Vol 2 (2) ◽  
pp. 54-60
Author(s):  
Inda Astri Aryani ◽  
Yulia Farida Yahya ◽  
Nina Roiana ◽  
Radema A Pranata
Keyword(s):  
Clinical Trial ◽  
Analogue Scale ◽  
Calcineurin Inhibitor ◽  
Severity Index ◽  
Randomised Clinical Trial ◽  
Double Blind Study ◽  
Double Blind ◽  
Seborrhoeic Dermatitis ◽  
The Face ◽  
The Mean

Background: Seborrhoeic dermatitis (SD) is a chronic papulosquamous inflammatory disease which resistant to medical treatment. Various treatment such as topical corticosteroid, antifungal and calcineurin inhibitor has been widely practiced and gives varying results Objective: Our objective was to compare the efficacy of Sebclaira® and topical hydrocortisone 2,5% for management of moderate SD on the face Methods: A randomised clinical trial, controlled, double blind study was performed for four weeks. We assessed the efficacy and side effects of these topical treatment. The severity of SD was evaluated using Seborrhea Area Severity Index-Facial (SASI-F) score. The severity of pruritus was evaluated using Visual Analogue Scale. Demographic characteristics, baseline SASI-F and VAS were recorded in the medical record. Results: A 34 patients (14 males, 20 females) with moderate SD on the face completed the four weeks study. The mean of SASI T2 and VAS score of the Sebclaira® group was significantly lower than Hydrocortisone 2.5% group with p = 0.000 and p = 0.000 respectively. Tolerance between Sebclaira® and Hydrocortisone 2.5% showed insignificant results (p = 1.000) Conclusions: The longer application of Sebclaira® was significantly more effective to improve moderate SD

scholarly journals Evaluation of ustekinumab treatment in psoriasis and the potential effect of metabolic syndrome on treatment response: a single center retrospective study

2020 ◽  
Vol 6 (4) ◽  
pp. 505
Author(s):  
Ömer Kutlu ◽  
Hatice M. Eksioglu
Keyword(s):  
Metabolic Syndrome ◽  
Treatment Response ◽  
Life Quality ◽  
Severity Index ◽  
Potential Effect ◽  
Effective Treatment Option ◽  
Plaque Type ◽  
Lower Response Rate ◽  
Psoriasis Disability Index ◽  
The Mean

<p class="abstract"><strong>Background:</strong> Ustekinumab is a biological agent used in the treatment of psoriasis. This study evaluated the treatment response of psoriasis patients who received ustekinumab.</p><p class="abstract"><strong>Methods:</strong> The study included nine patients with plaque-type psoriasis who received ustekinumab treatment. Clinical response of all patients was evaluated with psoriasis area and severity index (PASI), dermatology life quality index (DLQI), and psoriasis disability index (PDI) at 0, 4, 16 and 28 weeks. The patients were also evaluated for metabolic syndrome and its effect on treatment response.<strong></strong></p><p class="abstract"><strong>Results:</strong> A total of five male and four female patients with psoriasis vulgaris were included in the study. At the end of 28th weeks, 55% of the patients reached PASI 75 score. The mean PASI scores of the patients at weeks 0, 4, 16, 26 and 28 were 36.98±12.28, 8.86±9.06, 9.52±11.55, 3.55±3.61 and 6.98±6.40, respectively. Although not statistically significant, at the 28th weeks, the mean PASI, DLQI and PDI values of the patients with metabolic syndrome were higher than those without metabolic syndrome (p=0.505, p=0.314, p=0.786, respectively).</p><p class="abstract"><strong>Conclusions:</strong> Ustekinumab is an effective treatment option for patients with psoriasis who resistant to conventional and biological treatments. In resistant cases to the ustekinumab, the routine treatment interval should be reduced. Psoriasis patients with accompanying metabolic syndrome may have a lower response rate than those without metabolic syndrome to biological agents.</p>

scholarly journals Assessment of Quality of Life in a Sample of Iraqi Patients with Psoriasis.

2020 ◽  
Vol 29 (2) ◽  
pp. 161-168
Author(s):  
Sarah H. Abdulridha ◽  
Dheyaa J. Kadhim ◽  
Sarmad A. Abdul Razzak
Keyword(s):  
Quality Of Life ◽  
Negative Impact ◽  
Life Quality ◽  
Severity Index ◽  
Monthly Income ◽  
Psychosocial Effects ◽  
Significant Deterioration ◽  
Cross Sectional ◽  
The Mean

Psoriasis is a dermatological, chronic, immune-mediated condition. Psoriasis symptoms are not associated with physical burden only, but it may also have psychosocial effects on patients, diminished cognitive control, poor body image and impairments in everyday life. The value of quality of life is important since improving it is the principal goal for non-curative disease. The aim of the current study was to evaluate quality of life in a sample of Iraqi patients with psoriasis. This study is a cross-sectional study that involved 300 already diagnosed psoriasis patients who attended to the center of Dermatology and Venereology, Medical City/Baghdad. The mean age of patients was (35.156 ±10.549 years). The Arabic version of Dermatology Life Quality Index was used to assess quality of life.  The mean total score is 11.29± 5.45 and the majority of the patients (53.7%) had a total score of more than 10, which indicates a significant deterioration in patients’ quality of life. The greatest impact was found in symptoms and feelings (mean = 1.66 ± 0.75) while the lowest impact was noted in personal relationships (0.51± 0.65). Increasing age and monthly income as well as vulgaris type of psoriasis associated significantly better quality of life. While Psoriasis Area and Severity Index associated significantly worse quality of life. In conclusion, psoriasis exerts significant, negative impact on patients’ quality of life, especially among those with younger age, lower monthly income, high disease activity, and types of psoriasis other than vulgaris.   

scholarly journals Efficacy and safety of intralesional triamcinolone acetonide in the treatment of chronic hand eczema

2017 ◽  
Vol 10 (3) ◽  
pp. 129
Author(s):  
Tasnuva Ashraf ◽  
Harashit Kumar Paul ◽  
Md. Shahidullah Sikder ◽  
A. S. M. Zakaria ◽  
Saiful Islam Bhuiyan ◽  
...  
Keyword(s):  
Triamcinolone Acetonide ◽  
Severity Index ◽  
Hand Eczema ◽  
Clobetasol Propionate ◽  
Controlled Clinical Trial ◽  
Efficacy And Safety ◽  
Randomized Controlled ◽  
Chronic Hand Eczema ◽  
Group A ◽  
Group B

<p class="Abstract">This randomized controlled clinical trial was conducted to assess the efficacy and safety of intralesional triamcinolone acetonide in the treatment of chronic hand eczema comparing with topical clobetasol propionate. A total 60 patients of chronic hand eczema were recruited in the study. Thirty patients (Group A) were treated with intralesional triamcinolone acetonide and the rest 30 (Group B) with topical clobetasol propionate. Severity and improvement were assessed using Hand Eczema Severity Index (HECSI) score. The patients of both groups were followed up at 4<sup>th</sup> week and 12<sup>th</sup> week. In Group A, median HECSI score at baseline, 4<sup>th</sup> week and 12<sup>th</sup> week were 3, 20 and 20 respectively; whereas these scores were 54, 10 and 8 in Group B. In both groups, HECSI score was decreased gradually but the rate was higher in Group B than Group A (p&lt;0.05). Thinning of skin, an adverse effect, was seen in patients of both the intralesional triamcinolone acetonide (10%) and topical clobetasol propionate (16.7%) groups (p&gt;0.05). The result of this study demonstrates that intralesional triamcinolone acetonide is effective and safe in treating chronic hand eczema but less effective than the topical clobetasol.</p>

Sign in / Sign up

Export Citation Format

Share Document